Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 150 of 427 entries
View as:

Study of Safety and Efficacy of Avadomide (CC-122) Combined With RCHOP for Newly-diagnosed DLBCL With Poor Risk Factors

Phase: N/A Priority: Normal
NCT ID: NCT03283202 Org: User:
Start: 10/04/17 End: 12/16/20 Due: 12/16/21

A Study to Determine Dose and Regimen of Durvalumab as Monotherapy or in Combination With Pomalidomide With or Without Dexamethasone in Subjects With Relapsed and Refractory Multiple Myeloma

Phase: N/A Priority: Normal
NCT ID: NCT02616640 Org: User:
Start: 01/11/16 End: 07/30/24 Due: 07/30/25

A Study to Evaluate the Absorption, Metabolism, and Excretion of Orally Administered [14C]-BMS-986368 in Healthy Male Participants

Phase: N/A Priority: Normal
NCT ID: NCT06227975 Org: User:
Start: 02/02/24 End: 04/03/24 Due: 04/03/25

Efficacy and Safety Study of Ozanimod (RPC1063) in Relapsing Multiple Sclerosis Patients

Phase: N/A Priority: Normal
NCT ID: NCT01628393 Org: User:
Start: 09/18/12 End: 05/11/16 Due: 05/11/17

A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)

Phase: N/A Priority: Normal
NCT ID: NCT05519085 Org: User:
Start: 09/20/22 End: 11/30/33 Due: 11/30/34

Pomalidomide in Combination With Low-dose Dexamethasone or Pomalidomide in Combination With Low-dose Dexamethasone and Daratumumab in Subjects With Relapsed or Refractory Multiple Myeloma Following Lenalidomide-based Therapy in the First or Second Line Setting

Phase: N/A Priority: Normal
NCT ID: NCT01946477 Org: User:
Start: 05/29/14 End: 05/26/25 Due: 05/26/26

A Study to Determine the Recommended Dose and Schedule, and Evaluate the Safety and Preliminary Efficacy of Mezigdomide in Combination With Elranatamab in Participants With Relapsed and/or Refractory Multiple Myeloma

Phase: N/A Priority: Normal
NCT ID: NCT06988488 Org: User:
Start: 07/15/25 End: 06/03/27 Due: 06/03/28

A Study to Compare the Efficacy and Safety of BMS-986365 Versus the Investigator's Choice of Therapy in Participants With Metastatic Castration-resistant Prostate Cancer

Phase: N/A Priority: Normal
NCT ID: NCT06764485 Org: User:
Start: 03/13/25 End: 01/19/29 Due: 01/19/30

Study of Amrubicin in Patients With Small Cell Lung Cancer Refractory or Progressive to Prior Therapy

Phase: N/A Priority: Normal
NCT ID: NCT00375193 Org: User:
Start: 11/01/06 End: 03/01/09 Due: 03/01/10

Quality of Life in Metastatic Breast Cancer (MBC) Patients in Second Line Monochemotherapy

Phase: N/A Priority: Normal
NCT ID: NCT02403869 Org: User:
Start: 03/12/14 End: 01/31/19 Due: 01/31/20

A Long-term Active Treatment Study of Mongersen (GED-0301) in Subjects With Crohn's Disease

Phase: N/A Priority: Normal
NCT ID: NCT02641392 Org: User:
Start: 07/25/16 End: 01/04/18 Due: 01/04/19

Study of Azacitidine in Adult Taiwanese Subjects With Higher-Risk Myelodysplastic Syndromes (MDS)

Phase: N/A Priority: Normal
NCT ID: NCT01201811 Org: User:
Start: 10/01/10 End: 05/01/13 Due: 05/01/14

A Study to Evaluate the Effect of Food, Formulation Strength, and a Proton Pump Inhibitor on GED 0301 Pharmacokinetics in Healthy Adult Subjects

Phase: N/A Priority: Normal
NCT ID: NCT02957474 Org: User:
Start: 11/30/16 End: 12/31/16 Due: 12/31/17

A Study to Evaluate the Efficacy and Safety of Golcadomide in Combination With Rituximab in Participants With Newly Diagnosed Advanced Stage Follicular Lymphoma

Phase: N/A Priority: Normal
NCT ID: NCT06425302 Org: User:
Start: 08/30/24 End: 11/27/28 Due: 11/27/29

Study of Safety & PK of Luspatercept (ACE-536) in Pediatric Participants With Beta (β)-Thalassemia

Phase: N/A Priority: Normal
NCT ID: NCT04143724 Org: User:
Start: 11/07/19 End: 06/11/35 Due: 06/11/36

A Study to Evaluate the Efficacy and Safety of CC-93538 in Adult and Adolescent Japanese Participants With Eosinophilic Gastroenteritis

Phase: N/A Priority: Normal
NCT ID: NCT05214768 Org: User:
Start: 03/04/22 End: 09/11/25 Due: 09/11/26

A Study to Evaluate the Effect of Multiple Doses of CC-90001 on the Pharmacokinetics of Omeprazole, Midazolam, Warfarin, Rosuvastatin, Metformin, Digoxin, and Nintedanib in Healthy Adult Subjects

Phase: N/A Priority: Normal
NCT ID: NCT03363815 Org: User:
Start: 12/04/17 End: 07/29/18 Due: 07/29/19

A Study to Evaluate the Efficacy and Safety of JCAR017 in Adult Subjects With Relapsed or Refractory Indolent B-cell Non-Hodgkin Lymphoma (NHL)

Phase: N/A Priority: Normal
NCT ID: NCT04245839 Org: User:
Start: 07/14/20 End: 09/30/31 Due: 09/30/32

A Study to Determine the Efficacy and Safety of Lenalidomide in Patients With Mantle Cell NHL Who Have Relapsed or Progressed After Treatment With Bortezomib or Are Refractory to Bortezomib. The "EMERGE" Trial

Phase: N/A Priority: Normal
NCT ID: NCT00737529 Org: User:
Start: 12/22/08 End: 11/08/17 Due: 11/08/18

A Safety and Efficacy Study of CC-90011 in Participants With Relapsed and/or Refractory Solid Tumors and Non-Hodgkin's Lymphomas

Phase: N/A Priority: Normal
NCT ID: NCT02875223 Org: User:
Start: 08/31/16 End: 03/25/24 Due: 03/25/25

A Dose Finding and Safety Study of CC-220, Alone and in Combination With an Anti-CD20 Monoclonal Antibody (mAb) in Subjects With Relapsed or Refractory Lymphomas

Phase: N/A Priority: Normal
NCT ID: NCT04464798 Org: User:
Start: 11/11/20 End: 01/09/25 Due: 01/09/26

Expanded Access for AG-221

Phase: N/A Priority: Normal
NCT ID: NCT03723057 Org: User:
Start: - End: - Due: -

A Study to Assess the Effects of Itraconazole, Food, and pH on the Drug Levels of BMS-986368 in Healthy Participants

Phase: N/A Priority: Normal
NCT ID: NCT06170723 Org: User:
Start: 03/18/24 End: 05/25/24 Due: 05/25/25

Study of Pomalidomide in Persons With Myeloproliferative-Neoplasm-Associated Myelofibrosis and RBC-Transfusion-Dependence

Phase: N/A Priority: Normal
NCT ID: NCT01178281 Org: User:
Start: 09/08/10 End: 05/15/18 Due: 05/15/19

A Study to Determine the Efficacy and Safety of Luspatercept in Adults With Non Transfusion Dependent Beta (β)-Thalassemia

Phase: N/A Priority: Normal
NCT ID: NCT03342404 Org: User:
Start: 02/05/18 End: 11/28/22 Due: 11/28/23